stockrow
Friday 6 November 2026
Export BNTX’s income statement to Excel — free account
BioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
87.28
1.42
+1.65%
Follow BNTX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.09 | 7.05 | 7.81 | 8.99 | |
P/FCF ratio |
0.00 | 39.95 | 47.08 | 0.00 | |
P/Operating CF |
66.76 | (45.68) | 1,525.76 | (169.50) | |
P/B ratio |
1.06 | 1.03 | 1.14 | 1.20 | |
Price to Tangible BV |
1.18 | 1.15 | 1.27 | 1.32 | |
EV/Sales |
2.00 | 1.80 | 2.24 | 2.95 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
12.56 | 6.78 | 8.91 | (29.05) | |
EV/FCF |
(19.85) | 10.17 | 13.49 | (15.36) | |
Quick Ratio |
7.40 | 8.64 | 7.70 | 8.43 | |
Current Ratio |
7.54 | 8.80 | 7.85 | 8.55 | |
Net Debt/EBITDA |
73.50 | 25.78 | 21.18 | (31.54) | |
Debt/Assets |
1.22% | 1.44% | 1.55% | 1.78% | |
Debt/Equity |
0.01 | 0.02 | 0.02 | 0.02 | |
Asset Turnover |
0.13 | 0.14 | 0.13 | 0.11 | |
Operating CF/Net income |
(0.92) | 0.79 | (0.02) | (0.68) | |
Capex/Depreciation |
(0.25) | (0.64) | (0.19) | (0.14) | |
Interest Coverage |
(68.85) | (60.49) | (120.01) | 15.06 | |
Research and Development Expense of Revenue |
59.99% | 471.63% | 521.78% | 58.03% | |
Selling, General and Administrative Expense of Revenue |
25.42% | 127.69% | 187.31% | 13.85% | |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.09 | 0.08 | |
Share Based Compensation of Revenue |
1.84% | 17.53% | 7.35% | 1.21% | |
Graham Net Nets |
0.66 | 0.68 | 0.63 | 0.62 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.50%) | (6.62%) | (8.41%) | (6.96%) | |
Free Cash Flow Yield |
(1.42%) | 2.50% | 2.12% | (2.14%) | |
Revenue per Share |
4.07 | 0.55 | 0.48 | 5.95 | |
Operating CF per Share |
1.43 | (1.95) | 0.06 | (0.58) | |
Capex per Share |
(0.18) | (0.36) | (0.24) | (0.21) | |
Free Cash Flow per Share |
1.24 | (2.30) | (0.18) | (0.79) | |
Cash per Share |
69.64 | 67.65 | 67.83 | 67.67 | |
Shareholders Equity per Share |
89.99 | 86.41 | 81.50 | 81.76 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
89.99 | 86.41 | 81.50 | 81.76 | |
Free Cash Flow |
300.71 | (583.21) | (44.42) | (197.18) | |
Working Capital |
15,844.46 | 16,112.66 | 15,519.84 | 15,930.99 | |
Capital Expenditures |
(43.97) | (90.47) | (59.87) | (52.58) | |
Net Current Asset Value |
15,140.62 | 15,397.20 | 14,780.47 | 15,206.66 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.65 | 0.49 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1,371.67 | 888.76 | 952.71 | 908.29 | |
Average Payables |
533.46 | 508.11 | 662.14 | 534.71 | |
Average Inventory |
215.90 | 194.75 | 189.43 | 169.26 | |
Average Assets |
24,628.65 | 23,490.40 | 24,107.67 | 24,082.83 | |
Average Common Equity |
21,377.51 | 20,911.54 | 20,826.82 | 20,992.15 |
Columns are period end dates · fundamentals updated 5 Nov 2026